Bax accelerates tumorigenesis in p53-deficient mice.

Area of Science:

• Molecular Biology
• Cancer Research
• Cell Biology

Background:

• Bax is a pro-apoptotic member of the Bcl-2 family, counteracting Bcl-2's protective effects.
• Bax acts as a downstream effector of p53-induced apoptosis and is regulated by p53.
• Previous studies suggested Bax functions as a tumor suppressor, as Bax deficiency accelerated tumor onset in certain mouse models.

Purpose of the Study:

• To investigate the role of Bax expression levels in tumor development.
• To compare tumor incidence in Bax-deficient and Bax transgenic mice, with and without p53.
• To elucidate the dual roles of Bax in cell death and proliferation within different genetic contexts.

Main Methods:

• Comparison of spontaneous cancer incidence in Bax-deficient mice versus wild-type controls.
• Analysis of oncogenesis acceleration in mice deficient in both Bax and p53.
• Generation and study of Lck(pr)-Bax transgenic mice to assess the impact of BAX overexpression on T-cell development and tumorigenesis, with and without p53.

Main Results:

• Bax-deficient mice did not show an increased incidence of spontaneous cancers.
• Bax deficiency did not accelerate oncogenesis in p53-deficient mice.
• Lck(pr)-Bax transgenic mice exhibited increased apoptosis, and Lck(pr)-Bax/p53-deficient mice had a higher incidence of T-cell lymphomas compared to p53-deficient mice.
• Lck(pr)-Bax transgenic mice showed an increased percentage of cells in cycle, suggesting a role in proliferation.

Conclusions:

• Bax's role in tumorigenesis is context-dependent, capable of both accelerating and inhibiting tumor formation.
• BAX-induced proliferation, when combined with p53 deficiency, synergistically contributes to lymphomagenesis.
• Bcl-2 family proteins, including Bax, regulate both cell death and proliferation, impacting cancer development.